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Abstract
Rationale: Neurological complications of varicella-zoster virus (VZV) infection include cerebral infarction, meningoencephalitis,
segmental sensory disturbance, facial nerve palsy, and myelitis. Chronic myelitis is rarely reported. Diagnosis of VZV infection can be
conﬁrmed by elevated anti-VZV immunoglobulin G (IgG) antibody or detection of VZV DNA in the cerebrospinal ﬂuid (CSF), the former
reported to be superior. The detection rate of VZV DNA is generally thought to decrease with time after the onset of the condition. The
utility of VZV DNA polymerase chain reaction (PCR) is thus thought to be limited to the acute phase of the disease. The presence of
skin lesions also helps to render a diagnosis; however, cases of zoster sine herpete (ZSH), the occurrence of segmental symptoms
without skin lesions, renders the diagnosis of VZV infection more difﬁcult. Antiviral drugs, such as acyclovir, are the treatment of
choice to resolve VZV infections.
Patientconcerns:A 65-year-old Japanese man felt heaviness and a throbbing pain on the ulnar side of the right forearm. He was
previously diagnosed with cervical spondylosis, and received nonsteroidal anti-inﬂammatory drugs with little improvement. Contrast
cervical magnetic resonance imaging showed a swelling and an increased signal intensity of the spinal cord, and an enhancing lesion,
all of which were suggestive of myelitis.
Diagnosis: We found no evidence for diagnoses of sarcoidosis, Behçet disease, multiple sclerosis, or neuromyelitis optica
spectrum disorder. The CSF analysis revealed an elevation of the total protein concentration and that the patient was positive for VZV
DNA, while anti-VZV IgG was not elevated. The patient was therefore diagnosed with ZSH myelitis.
Interventions: We administered acyclovir and valaciclovir as the ﬁrst therapy. At the time of recurrence, we used high-dose
acyclovir, vidarabine, and high-dose methylprednisolone pulse therapy.
Outcomes:The patient’s dysesthetic pain in the right upper limb improved following the ﬁrst antiviral therapy. Twomonths later, he
suffered a recurrence, but the second therapy signiﬁcantly relieved his symptoms.
Lessons: VZV infection should be regarded as an important differential diagnosis of chronic myelitis. VZV DNA PCR should be
performed even in the chronic phase of the condition to introduce the possibility of antiviral therapy as a treatment option.
Abbreviations: AIDS= acquired immunodeﬁciency syndrome, CSF= cerebrospinal ﬂuid, Gd= gadolinium, HHS= hyperosmolar
hyperglycemic syndrome, MO = medulla oblongata, mPSL = methylprednisolone, MRI = magnetic resonance imaging, NTM =
nontuberculous mycobacteriosis, PCR = polymerase chain reaction, PSL = prednisolone, VZV = varicella-zoster virus, ZSH = zoster
sine herpete.
Keywords: acyclovir, chronic myelitis, varicella-zoster virus DNA, vidarabine, zoster sine herpeteEditor: N/A.
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11. Introduction
The varicella-zoster virus (VZV) is a DNA virus of the
herpesvirus family. Its primary infection causes chickenpox,
after which the virus establishes a lifelong latency in cranial
nerves and the dorsal root ganglia and can reactivate as herpes
zoster.[1] Neurological complications of herpes zoster include
vasculitis-induced cerebral infarction, meningoencephalitis, seg-
mental sensory disturbance, facial-nerve palsy (Hunt syndrome),
myelitis, and postherpetic neuralgia.[2] While the prevalence of
these complications among healthy individuals ranges from 0.1%
to 0.3%, it increases to 35% in immunocompromised patients.[3]
VZV can cause radicular pain without skin lesions (zoster sine
herpete, ZSH), sensorimotor neuropathy, and facial nerve
paralysis.[4] VZV myelitis often develops within the 3 weeks
following the appearance of a skin rash. Diagnosis of the
condition can be conﬁrmed with polymerase chain reaction
(PCR) detection of VZV DNA in the cerebrospinal ﬂuid (CSF);
Miyake et al. Medicine (2019) 98:32 Medicinethe rate of positive detection within 7 to 10 days after the
appearance of a rash is 61.5% to 100% but decreases to 25% to
44.4% thereafter.[2,5,6] Concerning ZSH, the rate of positive
detection is only 43% even within the 10 days following the
appearance of a skin lesion.[6] The time after onset of VZV
myelitis and the absence of skin lesions therefore comprise risk
factors of false negatives of PCR detection of VZV DNA in the
CSF. VZV DNA PCR is thought to be effective only in the acute
phase of the infection, especially in the case of ZSH; however,
obtaining sufﬁcient data to even consider ZSH as a potential
diagnosis is challenging.
We herein report a rare case of ZSH myelitis, diagnosed using
PCR detection of VZV DNA in the CSF despite a lapse of 10
months from the onset of the condition, and discuss the treatment
of recurrent VZVmyelitis based on the present case and previous
reports.2. Case presentation
A 65-year-old Japanese man felt heaviness and a throbbing pain
on the ulnar side of the right forearm. He consulted an
orthopedist and received an X-ray examination of the forearm,
which revealed no abnormality. Since his symptoms did not
improve naturally, the patient visited another orthopedist 6
months later. Magnetic resonance imaging (MRI) of the cervical
spine showed spinal canal stenosis and an abnormal signal of the
spinal cord. The patient was diagnosed with cervical spondylosis
and took nonsteroidal anti-inﬂammatory drugs, with little
improvement. Concurrently, the patient developed a few skin
lesions on the right ring ﬁnger as well as ﬂares on the ulnar side of
both palms with concomitant pain. He visited a dermatologist
and was diagnosed with dyshidrotic eczema, for which topical
corticosteroid was prescribed. One month later, he visited
another orthopedist who administered a contrast cervical MRI.
The examination revealed a cervical swelling at the C6/7 level, an
increased T2-weighted signal intensity of the spinal cord at the
C4–C7 level, and an enhancing lesion at C6, as well as a spinal
canal stenosis at the C5/6–C6/7 level. He was suspected of having
myelitis and was admitted to our hospital 10 months after the
initial symptoms had appeared.
His past medical history included treatment for hypertension,
Helicobacter pylori infection, and intraocular pressure elevation.
The patient reported no allergies. Our physical examination
revealed a body temperature of 36.2°C, blood pressure of 107/69
mm Hg, pulse rate of 73/min, respiration rate of 18/min, and
peripheral oxygen saturation of 97% in room air. The general
physical examination revealed several papules on the right ring
ﬁnger and elevated painful erythema on the ulnar side of both
palms, which again yielded a diagnosis of dyshidrotic eczema,
made by our dermatologist. Ophthalmologic examination
revealed no abnormalities, including uveitis and vitreous opacity.
He was alert and conscious. Neurological examination revealed
no remarkable ﬁndings in the cranial nervous system, no muscle
weakness or atrophy in any limb, no pathological reﬂexes, mildly
attenuated tendon reﬂexes in the upper extremities without
laterality, exaggerated tendon reﬂexes in the lower limbs, and
right-side dominance. The patient exhibited dysesthesia and
paresthesia on the ulnar side of the right hand and mild hypalgia
on the dorsum of both hands.
The complete blood cell count values, and indices of
coagulation and ﬁbrinolytic-system functioning were normal.
His hemoglobin A1c was 5.8%. Anti-VZV immunoglobulin M2(IgM) enzyme immunoassay (EIA) was 8.1 and anti-VZV
immunoglobulin G (IgG) EIA was <2.0. His angiotensin
converting enzyme level was 16.5 IU/L; soluble interleukin 2
receptor, 240U/mL; and lysozyme, 4.4mg/mL. All were within
normal limits. Antinuclear, anti-Sjögren’s-syndrome-related
antigen A, anti-Sjögren’s-syndrome-related antigen B, proteinase
3-anti-neutrophil cytoplasmic, and myeloperoxidase-anti-neu-
trophil cytoplasmic antibodies were not detected. The patient was
also reported to be negative for anti-aquaporin 4 and anti-myelin
oligodendrocyte glycoprotein antibodies. Hepatitis B surface
antibody was positive, but PCR-detection of hepatitis B virus
DNA was negative. Syphilis and human immunodeﬁciency virus
(HIV) were negative. The CSF analysis showed the following:
opening pressure of 105mm H2O; 1cell/mL (100% mononucle-
ar); total protein, 68mg/dL; glucose, 65mg/dL (146mg/dL in
the serum); anti-VZV IgM and IgG EIA, <2.0; angiotensin
converting enzyme, <1.0U/mL; soluble interleukin 2 receptor,
<50U/mL; interleukin-6, 1.77pg/mL; IgG index, 0.52; myelin
basic protein, <31.3pg/mL; and oligoclonal band, negative.
Neither the cytology study nor the comprehensive microbiolog-
ical analyses returned positive results. The type of human
leukemia antigen was A31/A24, B62/B52. The electrocardiogram
showed no atrioventricular blocks, and the chest X-ray revealed
no abnormalities. Computed tomography (CT) showed neither
malignancies nor lymphadenopathy, including hilum of lungs;
however, nodules at the right segment 3 (S3) and a ground glass
opacity at the ipsilateral S6 were noted. The sputum culture was
positive for Mycobacterium avium. Neither the cranial nor the
thoracolumbar MRI revealed abnormalities, whereas the con-
trast-enhanced cervical MRI showed disk bulging and thickening
of the yellow ligaments at the C5/6–C6/7 level, which compressed
the dural sac. A hyperintense lesion was observed in the right-
dorsal area of the cervical spine at the C6 level on T2-weighted
imaging (Fig. 1A and K), with heterogeneous contrast enhance-
ment (Fig. 1F and P). Gallium-67 scintigraphy revealed no
abnormal accumulations. No remarkable ﬁndings were gleaned
from the nerve conduction studies, a visual evoked potential test,
or a somatosensory evoked potential test.
We found no indication of sarcoidosis, Behçet disease, multiple
sclerosis, or neuromyelitis optica spectrum disorder; we therefore
tentatively diagnosed the patient with cryptogenic myelitis
complicated with cervical spondylosis. High-dose methylpred-
nisolone (mPSL) pulse therapy (1g/day, for 3 days) was
administered with marginal improvement of dysesthesia in the
right upper limb, and the patient was discharged. Two weeks
later, his symptoms worsened again. The number of VZV DNA
in the CSF drawn at the ﬁrst hospitalization was subsequently
found to be 490copies/mL, and the patient was suspected of
having VZV myelitis without skin lesions: ZSH myelitis. He was
readmitted to our hospital and was treated with intravenous
acyclovir (5mg/kg/day) for 2 weeks. Six days after the
commencement of the therapy, the frequency of dysesthetic pain
decreased and the range of the pain declined (Fig. 2). Contrast-
enhanced cervical MRI showed shrinkage of the spinal lesion and
attenuation of the contrast enhancement (Fig. 1B, G, L, and Q).
The patient was further treated with high-dose mPSL pulse
therapy followed by oral prednisolone (PSL) (30mg/day), which
was followed by a slight worsening of the pain. PSL was ended
gradually, and the patient received oral valaciclovir (300mg/day)
for 1week and pregabalin (gradually increased up to 375mg/day)
while the intermittent pain around the little ﬁnger persisted. The
patient only experienced slight dysesthetic pain on discharge, but
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Figure 1. (A–E) Magnetic resonance images of the cervical spine. The ﬁrst row shows the T2-weighted midsagittal images; the second, gadolinium-enhanced T1-
weighted midsagittal images; the third, T2-weighted axial images at the C6/7 level; the fourth, gadolinium-enhanced T1 weighted axial images at the same level as
the third. (A) On the ﬁrst admission: high intensity lesion was at the C5–C7 level, with partial gadolinium enhancement. (B) After treatment with acyclovir (5mg/kg/
day, 14 days) and valacyclovir (3000mg/day, 7 days): the cervical lesion was reduced and the gadolinium enhancement was attenuated. (C) On the third admission:
the expansion of the cervical lesion and its enhancement were seen. (D) After treatment with acyclovir (30mg/kg/day, 14 days): the cervical lesion was slightly
reduced. (E) After treatment with vidarabine (15mg/kg/day, 10 days): the gadolinium enhancement at the C6 level was weakened.
Miyake et al. Medicine (2019) 98:32 www.md-journal.comhis symptoms worsened again 2 months later. Enlargement of the
spinal lesion was clearly observed on contrast-enhanced cervical
MRI (Fig. 1C, H, M, and R), and the patient was admitted again
for treatment. VZV DNA in the CSF was not detected, but based
on the clinical course, relapse of ZSH myelitis was strongly
suspected. After the administration of 30mg/kg of acyclovir for 2
weeks, a cervical MRI showed a reduction of the lesion with a
remaining but reduced contrast enhancement at the C6 level
(Fig. 1D, I, N, and S). We then administered 15mg/kg of
vidarabine for 10 days and high-dose mPSL pulse therapy. The
patient reported that the dysesthetic pain in the right arm was
reduced to about 10% to 20% of that at the time of
hospitalization. Cervical MRI revealed attenuation of the
contrast enhancement (Fig. 1E, J, O, and T). Following discharge,
he continued to regularly visit our hospital; there was no
worsening of the pain.
As this is a case report, obtaining of ethical approval was not
necessary. The patient and his family provided written informed
consent for the publication of his clinical data. The presented data
are anonymized and the risk of identiﬁcation is minimal.33. Discussion
We herein report the case of a patient with VZV-associated
chronic myelitis who developed dysesthetic pain on the right
upper limb and whose diagnosis was ascertained using VZV
DNA PCR of the CSF. Spinal MRI of patients with VZV myelitis
is often reported to exhibit a low signal in T1-weighted images, a
high signal in T2-weighted images, and gadolinium (Gd)
enhancement. The contrast enhancement is considered to be
an especially useful indicator of inﬂammation or necrosis of the
spinal lesion.[4,7] Akin to previous reports, our patient was found
to exhibit a cervical lesion with an abnormal signal and Gd
enhancement; however, it was challenging to distinguish myelitis
from cervical spondylotic myelopathy because the spinal lesion
was situated at the stenotic site of the spinal canal. Kang et al[8]
previously reported a case of segmental zoster paresis, in which
the patient suffered from muscle weakness in the left upper limb.
The cervical MRI performed localized the spinal lesion to the
same level as the spinal canal stenosis, rendering the diagnosis of
myelitis difﬁcult. In their case, CSF analysis was not performed
because the patient did not provide consent.[8] In the present case,
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Figure 2. Clinical course. CSF=cerebrospinal ﬂuid, mPSL=methylprednisolone, PSL=prednisolone.
Miyake et al. Medicine (2019) 98:32 Medicineadministration of antiviral medicine dramatically improved the
patient’s clinical symptoms and reduced his cervical spinal lesion,
suggesting that VZV-associated myelitis was the main cause of
the dysesthetic pain in his arm; however, the possibility that
cervical spondylosis partially contributed to his symptoms
remains. Careful differentiation of viral myelitis and cervical
spondylosis is required because the conditions require entirely
different treatment strategies.
Neurological complications of VZV infection are often
associated with immunodeﬁcient conditions; malignant lympho-
ma, leukemia, metastatic tumor, HIV infection, renal failure, and
systemic lupus erythematosus have been identiﬁed as the
contributory diseases.[9] Patients with these diseases often exhibitTable 1
Comparison of the present ﬁndings with those of previous studies o
References Age Sex
Underlying
disease
Period from
onset to treatment
Move
diso
Heller et al 1990[11] 31 M None 23 days Parapl
Chrétien et al 1993 [12] 30 M AIDS 1 month None
Gray et al 1994 [13] 42 M AIDS 3 days Parapl
Meylan et al 1995 [14] 35 M AIDS 3 weeks Parapl
Manian et al 1995 [15] 41 M AIDS 2 months Tetrap
Inukai et al 2010 [16] 55 F None 1 month None
Hung et al 2012 [17] 77 M HHS Acute Parapl
Present case 65 M NTM 13 months None
0=good outcome, 1=poor outcome, 2=death, A=acyclovir, AIDS= acquired immunodeﬁciency syndrom
HHS=hyperosmolar hyperglycemic syndrome, M=male, MRI=magnetic resonance imaging, NTM=non
valacyclovir.
4ZSH, VZV-associated neurologic symptoms without rash, and
the consequent symptoms: sensory and/or motor neuropathies,
facial nerve paralyses, and/or persistent radicular pain.[10] On the
other hand, ZSH without immunodeﬁciency, as was exhibited in
our patient, has also been reported.[10,11] Our systemic analyses
revealed neither HIV infection nor malignancy, and although
chest CT and sputum culture revealed that our patient had
nontuberculous mycobacteriosis, this ﬁnding did not indicate
severe immunodeﬁciency.
We compared the present case with prior reports of ZSH
myelitis (Table 1).[11–17] In our case, the proximity of the spinal
lesion to the posterior funiculus likely accounts for the patient not
having experienced muscle weakness in the extremities. Then zoster sine herpete myelitis.
ment
rder
MRI
level CSF Treatment Outcome
Cell (/mL) Protein (mg/dL)
egia T12 23 136 A, S 0
C3–7 210 2380 C 2
egia C4–7 76 High G 2
egia T9–10 32 684 U 2
legia MO upper C 20 Normal A 1
C2 1 19 A, VA, S 0
egia None U U None 0
C5–7 1 68 A, VA, S 0
e, C= anti-cytomegalovirus drug, C= cervical, CSF= cerebrospinal ﬂuid, F= female, G=ganciclovir,
tuberculous mycobacteriosis, S= steroid, T= thoracic, MO=medulla oblongata, U=unknown, VA=
Miyake et al. Medicine (2019) 98:32 www.md-journal.compresent case was characteristic of the mild and chronic course of
myelitis with a longer period from onset to treatment, while
majority of the cases were acute or subacute course of the disease,
and often lethal. The CSF ﬁndings were mild in our case, with
only slight elevation of proteins without pleocytosis, making the
consideration of VZV myelitis as a differential diagnosis more
difﬁcult in our case. In contrast, the majority of the other cases
demonstrated pleocytosis and elevation of proteins, a more
typical CSF presentation of VZV myelitis.[18] Although detection
of VZV DNA in the CSF is useful for the diagnosis of VZV
myelitis,[2] the detection rate of VZV DNA reportedly declines
with time after the onset.[5,6] Hence, the detection of VZV DNA
in the CSF in the present chronic case was surprising. Moreover,
the absence of characteristic skin lesions is another risk factor for
the failure to detect VZV DNA.[6] The possibility of contamina-
tion was not likely because, in contrast to the ﬁrst round of mPSL
pulse therapy, the administration of acyclovir and valaciclovir
signiﬁcantly improved the patient’s clinical symptoms and
reduced his cervical lesion. Interestingly, the clinical picture in
our case was almost identical to the 2 milestone cases of ZSH
reported by Gilden et al that were the ﬁrst 2 cases of ZSH
demonstrating VZV DNA in the CSF, providing virological
evidence of ZSH to establish ZSH as the clinical variant of VZV
infection.[10] VZV DNA was detected in the CSF 5 and 8 months
after the onset of radicular pain, with a chronic disease course, no
pleocytosis and no/mild elevation of proteins in the CSF.[10] Thus,
VZV DNA PCR of the CSF remains useful even in cases of
chronic myelitis. Although the detection of anti-VZV IgG
antibody in the CSF is reported to be superior to VZV DNA
PCR of the CSF for the diagnosis of VZV vasculopathy, recurrent
myelopathy, and brainstem encephalitis produced by VZV,[18,19]
cases such as ours indicate that both VZV DNA PCR and anti-
VZV IgG antibody in the CSF must be tested to exclude chronic
VZV myelitis.[18]
Administration of acyclovir can effectively treat cases of VZV
myelitis without severe immunodeﬁciency.[8,13,14] On the other
hand, there have been several reports concerning recurrent VZV
myelitis, for which there is no established treatment strate-
gy[7,18,20]: acyclovir has mainly been used, while valaciclovir and
famciclovir have been proposed as alternative candidates for
treatment.[9,19,20] In the present case, we ﬁrst treated the patient
with 15mg/kg of intravenous acyclovir for 2weeks and 3g of oral
valaciclovir for 1 week, but he suffered a recurrence 2 months
after the therapy. We then administered 30mg/kg of acyclovir,
the dosage used to treat VZV encephalitis, for 2 weeks and 15mg/
kg of vidarabine for 10 days; this strategy has hitherto forestalled
recurrence. Therefore, a sufﬁcient dosage of acyclovir and
addition of vidarabine may be effective for the treatment of
recurrent VZV myelitis. The use of steroids in addition to
antiviral drugs is also reportedly effective for the improvement of
clinical symptoms associated with VZV infection.[10,15] In our
case, high-dose mPSL therapy evinced the limited effect of the
slight relief of the patient’s dysesthetic pain, possibly due to
reduction of the spinal edema. Oral corticosteroids did not
improve his condition; it is therefore doubtful that continuous
administration of steroids improves prognosis.4. Conclusion
Diagnosis of ZSH myelitis was made possible in the present case
via the detection of VZV DNA in the CSF despite the relatively5long period between the onset and diagnosis. In addition,
antiviral drugs signiﬁcantly relieved the patient’s symptoms and
reduced the cervical spinal lesion. A diagnosis of VZV infection
should be considered even in cases of chronic myelitis.Acknowledgments
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